Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.


Barrett's columnar-lined oesophagus is the precursor lesion for oesophageal adenocarcinoma. The overall rate of progression to adenocarcinoma is 0.59% per annum. A large prospective multicentre trial is recruiting to assess the role of aspirin as a chemoprotective agent in prevention of development of cancer as well as cardiovascular protection in patients… (More)
DOI: 10.1097/CEJ.0b013e32832e0955


  • Presentations referencing similar topics